-
Product Name
Anti-Sclerostin/SOST antibody
- Documents
-
Description
Rabbit monoclonal to Sclerostin/SOST
-
Tested applications
ELISA, IP
-
Species reactivity
Human Sclerostin / SOST
-
Alternative names
5430411E23Rik antibody; RP23-398F7.2 antibody; sclerosteosis antibody; Sclerostin antibody; Sclerostin antibody; Sost antibody; SOST antibody; VBCH antibody; VBCH antibody; SOST1 antibody; 5430411E23Rik antibody; CDD antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human Sclerostin / SOST (rh Sclerostin / SOST; NP_079513.1; Gln24-Tyr213).
-
Clonality
Monoclonal
-
Formulation
0.2 μm filtered solution in PBS
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL μg/ml with the appropriate secondary reagents to detect Human Sclerostin / SOST.
IP: 0.5-2 uL/mg of lysate
-
Validations
Sclerostin / SOST Antibody, Rabbit MAb, Immunoprecipitation
-
Background
Sclerostin, the protein product of the SOST gene, is a potent inhibitor of bone formation. Sclerostin protein is widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteeoblasts differentiated for 21 days, and was originally identified as an important regulator of bone remodeling, homeostasis, and links bone resorption and bone apposition. Recent studies have revealed that Sclerostin protein inhibits the bone growth probably by binding to the extracellular domain of the Wnt coreceptors LRP5 and LRP6 and disrupting Wnt-induced Frizzled-LRP complex formation.
-
References
- Bellido T. (2006) Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact. 6(4): 358-9.
- van Bezooijen RL, et al. (2007) SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev Dyn. 236(2): 606-12.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"